Penumbra/$PEN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Penumbra
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
- Ticker
- $PEN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 4,700
- Headquarters
- Alameda, United States
- Website
- www.penumbrainc.com
Penumbra Metrics
BasicAdvanced
$13B
80.63
$3.97
0.70
-
Price and volume
Market cap
$13B
Beta
0.7
52-week high
$362.41
52-week low
$225.52
Average daily volume
381K
Financial strength
Current ratio
5.888
Quick ratio
3.716
Long term debt to equity
0.121
Total debt to equity
0.132
Interest coverage (TTM)
84.37%
Profitability
EBITDA (TTM)
209.161
Gross margin (TTM)
67.98%
Net profit margin (TTM)
10.06%
Operating margin (TTM)
12.13%
Effective tax rate (TTM)
24.45%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
6.28%
Return on equity (TTM)
10.67%
Valuation
Price to earnings (TTM)
80.635
Price to revenue (TTM)
8.062
Price to book
7.97
Price to tangible book (TTM)
8.94
Price to free cash flow (TTM)
62.802
Free cash flow yield (TTM)
1.59%
Free cash flow per share (TTM)
5.096
Growth
Revenue change (TTM)
16.98%
Earnings per share change (TTM)
-4.10%
3-year revenue growth (CAGR)
16.18%
10-year revenue growth (CAGR)
20.36%
3-year earnings per share growth (CAGR)
55.59%
10-year earnings per share growth (CAGR)
21.69%
What the Analysts think about Penumbra
Analyst ratings (Buy, Hold, Sell) for Penumbra stock.
Analyst projections of the future price of Penumbra stock.
Bulls say / Bears say
Third-quarter 2026 revenue rose 15.6% to $410.1 million, led by 18.1% growth in thrombectomy; US venous thromboembolism revenue grew 26%. This points to continued demand across Penumbra’s core business. (Penumbra Inc)
Gross margin rose to 68.3% from 67.8% a year earlier, while operating income increased to $50.7 million from $48.8 million. The higher margin and operating profit suggest product mix and scale are helping profitability. (Penumbra Inc)
THUNDERBOLT has FDA clearance and a European CE Mark for stroke treatment, expanding Penumbra’s potential market. In its 216-patient THUNDER study, 87.5% of cases met the successful reperfusion measure, although the study was single-arm. (Penumbra Inc, Penumbra Inc)
Earnings have not kept pace with sales: third-quarter net income fell to $42.3 million from $45.9 million and diluted EPS declined to $1.07 from $1.17, despite 15.6% revenue growth. (Penumbra Inc)
Penumbra says it competes with larger, well-funded companies and must keep introducing devices that specialist clinicians adopt. If new products fail to gain traction or supply cannot keep up, growth could suffer. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
Penumbra Financial Performance
Revenues and expenses
Penumbra Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Penumbra
AllUSDEURGBP
Fund name | Fund size | $PEN weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.37% |
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.37% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.20% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.20% |
iShares MSCI World Small Cap$WSML | $9B | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.